UNICHEMLAB530.00

Unichem Laboratories Limited

· Pharma & Health
₹ CrorePeersGUFICBIORPGLIFEGUJTHEMSMSPHARMAORCHPHARMAINDSWFTLABSOLARAFDCMcap ₹3,731 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation113.2124.6125.1
+ Finance Costs22.721.031.5
+ Interest Income0.00.0-5.3
+ Fair Value (Gains) / Losses-6.40.7-2.3
+ Share-based Payments3.12.10.8
+ Unrealised FX (Gain) / Loss-1.04.0-5.9
+ Other Non-cash Items126.20.156.1
+ Other — Cash Effects are Investing / Financing-69.6-1.0-273.0
Changes in Working Capital
+ Inventories-79.4-252.513.8
+ Trade Receivables — Current-25.1-39.0-20.9
+ Other Financial Assets — Current0.00.00.0
+ Other Financial Assets — Non-current2.00.00.0
+ Other Current Assets-33.80.00.0
+ Other Non-current Assets40.50.00.0
+ Trade Payables — Current8.7-2.4-201.0
+ Other Current Liabilities-7.10.00.0
+ Provisions — Current-8.40.00.0
Cash from Operating Activities
Profit Before Tax (per I/S)-61.7154.6292.4350.4
+ Total Adjustments (incl. Working Capital)85.4-142.3-281.2
Cash from Operations (pre-tax)23.812.311.2
+ Interest Received — Operating-0.7-2.90.0
+ Dividends Received — Operating-0.00.00.0
+ Income Taxes Paid6.416.47.6
Cash from Operating Activities16.7-7.03.6
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)22.5137.4123.0
+ Disp of Fixed Assets8.92.2282.6
+ Sale of Investments (Equity / Debt)65.21.40.0
+ Acq of Subsidiaries / Businesses (net)0.084.50.0
+ Disp of Subsidiaries / Businesses (net)0.00.04.0
+ Dividends Received — Investing0.00.00.0
+ Interest Received — Investing0.61.75.6
+ Other Inflows / (Outflows) — Investing-1.8-24.622.9
Cash from Investing Activities50.4-241.2192.1
Cash from Financing Activities
+ Proceeds from Borrowings0.0235.275.3
+ Repayment of Borrowings78.525.741.9
+ Payment of Lease Liabilities5.45.96.3
+ Interest Paid22.219.624.9
+ Dividends Paid0.20.30.0
+ Other Inflows / (Outflows) — Financing0.00.0-0.4
Cash from Financing Activities-106.3183.81.9
Net Changes in Cash (pre-FX)-39.2-64.5197.6
+ Effect of FX Rate Changes on Cash6.4-0.72.3
Net Changes in Cash-32.8-65.2199.9
Closing Cash150.9
Reference Items
EBITDA100.2264.9184.2228.6
EBITDA Margin %5.8812.558.369.90
Free Cash Flow (CFO − Capex)-5.9-144.4-119.4-119.4
Free Cash Flow to Equity46.9-105.5
Free Cash Flow per Basic Share-0.83-20.51-16.96-16.96
Cash Flow to Net Income-0.24-0.050.01
Cash Paid for Taxes6.416.47.6
Cash Paid for Interest22.219.624.9
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.